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Abstract 
PURPOSE: Obesity costs the U.S. roughly $147 billion in health care spending annually.  There 
has been a call for healthcare providers to initiate all possible weight loss interventions.  One 
treatment strategy not used to its fullest potential is that of prescribing antiobesity medications.  
The purpose of this project was to examine and evaluate the effectiveness of three common 
weight loss medications used in the treatment of obesity, including discussion and 
recommendations. 
METHODS:  This project was a single-center retrospective study comparing three different 
groups of patients seen at a rural weight loss clinic. The sample consisted of 84 patients seen 
between September 2014 to September 2017. Three groups taking Adipex, Adipex + Contrave, 
and Apidex + Saxenda were evaluated for effectiveness on weight loss, BMI, and waist 
circumference.  Compliance to medications, diet, and exercise were evaluated.  
RESULTS: Each medication group proved to be effective in treating obesity.  On average, 
patients taking Adipex had 7.2% weight loss, Adipex + Contrave had 7.2% weight loss, and 
Adipex + Saxenda averaged 9.1% weight loss.  Compliance to diet and exercise was a 
determinant for weight loss success.  Those that did not comply to the medication regimen or a 
diet and exercise plan did not decrease obesity measures. 
CONCLUSION:  Pharmacotherapy is an adjunctive therapy to diet and exercise. No differences 
in the effectiveness of medication between groups was found; however, each medication was 
statistically proven to be effective in obesity reduction.  Adipex, while proving just as effective 
as combination therapy, is the most affordable and when applicable should be considered along 
with diet and exercise for those seeking weight loss.   
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A Retrospective Comparative Analysis on the Effectiveness of Pharmacologic Weight Loss  
 
Introduction 
 
In a recent survey, Americans ranked obesity as the top health concern in the country 
(State of Obesity, 2017).  As obesity-related health issues continue to escalate, Americans seek 
to reverse the trend by taking an interest in personal health and wellness by reaching for the “all 
natural” or “organic” labels, hitting the gym, and fad dieting (Walsh, 2015).  Perhaps this trend is 
why 502 billion dollars are spent by consumers on prevention and wellness products (e.g. 
vitamins, nutritional supplements, over the counter weight loss supplements, and fortified foods) 
(Accenture, 2014).  Health and wellness has been called “the next trillion-dollar marketplace” 
and projected to grow 50% over the next five years (Accenture, 2014; Cloos et al., 2012).  There 
is a growing use of anti-obesity medications to help those who simply are not successful in 
losing weight. The purpose of this project was to provide a retrospective analysis comparing the 
effectiveness of three weight loss medications on weight, body mass index (BMI), and waist 
circumference used in one weight loss clinic.   
Background & Scope 
Global 
According to the World Health Organization (WHO) (2018), an estimated 2.8 million 
people die each year secondary to being overweight or obese.  The prevalence of overweight and 
obesity is highest in North America (62% overweight, 26% obese) and lowest in South East Asia 
(14% overweight, 3% obese) (WHO, 2018).  Between 1980 and 2014, obesity rates more than 
doubled worldwide (Manchi & de Melo, 2017).  As of 2014, the WHO reported more than 1.9 
billion adults over age 18 were overweight (38% men, 40% women); of those, over 600 million 
were obese (11% men, 15% women) (2016).  
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National 
With an estimated 150 billion dollars spent on obesity related health care annually, and 
billions more in production loss, obesity is now considered the most prevalent chronic disease in 
the United States (Kim & Basu, 2016; Winterfield & Cauchi, 2014).  As of 2011, a projected 
cost of over 11 billion dollars was spent on medical costs for obese adults in the U.S. (The State 
of Obesity, 2015).  Obesity rates exceeded 35% in five states (West Virginia, Mississippi, 
Alabama, Arkansas, and Louisiana); nationally, nearly 8% of adults fall into the extremely obese 
(BMI >40) category (State of Obesity, 2017).  Interestingly, in 1985, no state had an adult 
obesity rate exceeding 15% and in 2006, only Mississippi was above 30% (State of Obesity, 
2017).   
In Table 1, gender demographics for obesity are outlined (see Table 1).  Statistically 
significant differences were seen in obesity rates and ethnicity.  The highest prevalence is noted 
in the Black community followed by Hispanics and then Caucasians.  Level of education and 
income have been recognized as factors in the prevalence of obesity.  Of those who did not 
graduate high school, 33% were found to be obese compared to 22% of those who went to 
college or technical college (State of Obesity, 2017).  More than 33% of adults who earned less 
than 15,000 dollars per year were obese compared to 24.5% who earned at least 50,000 dollars 
per year (State of Obesity, 2017).   
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Table 1. 
National Obesity Rates, 2017 
National Obesity Rates, 2017 
 Men & Women Men Women 
Overall 38% 35% 40.4% 
Blacks 57.2% 38% 38% 
Latinas 46.9% 37.9% Unknown  
Whites 38.2% 34.7% 34.7% 
Asians 12.4% Unknown Unknown  
Note: data from the State of Obesity Annual Reports. Retrieved from http://www.stateofobesity.org/obesity-rates-
trends-overview/ (2017). 
 
The 2017 State of Obesity Annual Report recorded a decline in obesity rates for 2016 in 
four states (Minnesota, Montana, New York, & Ohio).  This is the first time a reduction has been 
seen since data collection; yet, obesity remains one of America’s most prevalent health 
problems.  The etiology centers on the American lifestyle when one evaluates reported current 
diet and exercise patterns.  Less than half of Americans meet U.S. aerobic guidelines, greater 
than 70% do not meet the recommended daily servings of fruits or vegetables, approximately 
49% of adults drink a sugar-sweetened beverage per day, and most exceed recommended levels 
of solid fats, added sugar, and sodium (State of Obesity, 2017).   
Local.  Kentucky is currently ranked seventh for highest rate of obesity in the country 
with a rate of 34.2% (State of Obesity, 2017).  Kentuckians living in rural areas, particularly the 
Appalachian region, have a higher prevalence of being overweight or obese, and have more 
obesity-related health conditions than those living in other state rural regions (Schoenberg et al, 
2013).  Alarmingly, between 2008-2010, two in three adult Kentuckians were overweight 
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(67.1%) and three in ten (31.5%) were obese (Walsh et al., 2012).  Seven in ten (70.1%) of 
Appalachian adults were overweight and one in three (34.6%) were obese (Walsh et al., 2012).  
According to the State of Obesity Annual Reports (2012), those living in the Appalachian region 
have experienced an increase in the prevalence of obesity in the past eight years.  
The Appalachian communities are socioeconomically impoverished and have decreased 
access to health care.  There is a higher prevalence of smoking, poor eating habits, inactivity, and 
mental health disorders (Schoenberg, Huang, Seshadri, & Tucker, 2015).  According to the most 
recent data, 28.4% of those living in the Appalachian region are physically inactive (Marshall & 
Alcalde, 2017).  As of 2011, 17% of Kentuckians forego medical care due to cost and 16% have 
no personal health care provider (Walsh et al., 2012).   
Affordability of high quality food, insufficient transportation, and geographic locations 
were described by Appalachian residents as some of the greatest barriers for battling obesity 
(Schoenberg et al., 2015).  One resident from Harlan county stated, “When McDonald’s opened, 
their opening day here surpassed any other openings in the United States.” (Schoenberg et al., 
2015).  Many Appalachian residents know a “Big Mac” may not be the healthiest option but will 
accept the consequences due to convenience or the marketing of the item influences them 
(Schoenberg et al., 2015).  This information is alarming and demonstrates the need for rural 
health care and obesity education. 
Obesity Risks 
With obesity and associated factors costing healthcare billions annually, and coupling this 
with its comorbidities and chronicity, obesity is now considered a disease by healthcare 
professionals (Garvey et al., 2016).  Morbidity and mortality of obesity-related conditions make 
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obesity a necessary target for intervention.  Clearly healthcare providers must be fully engaged in 
helping patients reach a healthy weight and use all avenues for treatment (Garvey et al., 2016).  
The obesity epidemic raises the need for preventive care.  Obesity alone is a major risk 
factor in cardiovascular, orthopedic, and metabolic disorders (Emmett & Chandra, 2015).  
Weight-related complications include: type 2 diabetes, dyslipidemia, hypertension, 
cardiovascular disease, nonalcoholic fatty liver disease, polycystic ovary syndrome, female 
infertility, male hypogonadism, obstructive sleep apnea, asthma/reactive airway disease, 
osteoarthritis, urinary stress incontinence, gastroesophageal reflux disease, and depression 
(Garvey et al., 2016).   Each of these conditions can be medically managed.  However, with 
clinically significant weight reduction, each of these comorbidities could be remedied without 
medication (Garvey et al., 2016).  
Bias 
Obesity is a major and growing problem, but how do you convince society of the need for 
change?  Emmett and Chandra (2015) conducted a study examining people’s perception of how 
great a problem obesity is in the U.S.; a total of 692 Americans replied to surveys.  The majority 
(94.4%) were aware that obesity is a major and growing problem (Emmett & Chandra, 2015).  
This study found that people correlated obesity with diet (p. 96).  Making people aware of the 
consequences and causes of obesity is the first step in addressing this epidemic.  
An unfortunate consequence many obese adults face is that of weight stigmatization 
(Puhl, Quinn, Weisz, & Suh, 2017).  Weight stigmatization, or negative societal devaluation of 
people based of their excess body weight, is a form of prejudice (Puhl et al., 2017).  Recent 
studies show a relationship between obesity and psychological disorders (Collins, Meng, & Eng, 
2016).  Numerous studies report obese individuals claiming lower quality of life, decreased life 
7 
 
satisfaction, anxiety, and higher incidence of depression (Collins et al., 2016; Lin et al., 2013). 
Remarkably, the correlation between obesity and psychological disorders appears bidirectional; 
psychological disorders may develop obesity and obese may develop psychological disorders 
(Collins et al., 2016).   
Vast instances of weight derogatory comments, verbal aggression, and cyber-bullying 
occur daily on social media (Brun, McCarthy, McKenzie, & McGloin, 2014; Chou, Presin, & 
Kunath, 2014).  Meta-analyses show weight bias has negative impacts on job related outcomes 
(hiring, salary, promotion status) (Roehling, Pichler, & Bruce, 2013; Vanhove & Gordon, 2014).  
Evidence validates the correlation between weight stigmatization, adverse health behaviors, and 
outcomes leading to weight gain such as increased risk of depression, stress, binge eating, or 
reduced physical activity (Puhl et al., 2017).  Currently, in the United States, obese individuals 
have little to no legal protection against weight-based discrimination (Pearl, 2018).  There needs 
to be strategies to decrease weight bias and discrimination in the workplace, schools, and media 
(Pearl, 2018).   
Constant media attention about obesity-related topics continue to invade broadcasting.  
The healthcare community has been found to harbor negative views about those who are 
overweight or obese (Puhl, 2017).  Fortunately, there does seem to be some movement by 
primary care providers (PCPs) in addressing obesity.  According to a study by Mehta et al. 
(2012), PCPs were 2.38 times more likely to provide obesity management compared to 
specialists (i.e. Gastroenterologists, Endocrinologists, Gynecologists).   Further, patients who had 
preventive visits and/or chronic visits were more likely to receive obesity management over 
patients who only had acute visits (Mehta et al., 2012).  Mehta et al. (2102) reports that more 
time spent with a PCP, the number of comorbid conditions, and a BMI ≥40 significantly 
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increased the likelihood of receiving obesity management.  Elderly or those who smoke were 
less likely to receive obesity treatment (Mehta et al., 2012).  Other studies report health care 
professionals as having less respect for obese patients believing they are unmotivated, lazy, and 
unlikely to be compliant with treatment recommendations (Phelan et al., 2015; Puhl, Phelan, 
Nadglowski, & Kyle, 2016).  
Stakeholders 
There are a number of stakeholders seeking to address the obesity epidemic.  In 2013, 
governmental agencies on the federal, state, and local level began to institute changes that would 
address the growing problem of obesity.   School food programs, propositioning initiatives to tax 
or ban certain foods and beverages, and proposed changes in nutrition labeling have been 
directed at improving American’s nutrition (Slavin, 2015).  These address primary prevention, 
which is easier than addressing obesity.   
Countless health care organizations have developed programs of research focused on new 
technology (bariatric surgery), medications, and policy advancements for decreasing obesity.  
The American Association of Clinical Endocrinologists (AACE) Board of Directors and 
American College of Endocrinology (ACE) Board of Trustees published standardized clinical 
practice guidelines (CPGs).  Each have provided recommendations for comprehensive medical 
care of patients with obesity based on a diligent review of the clinical evidence (Garvey et al., 
2016).   
Current Practice Guidelines & Theory 
AACE/ACE Guidelines 
The CPGs for comprehensive medical care of patients with obesity include evidence for 
definitions, goals, and methods for phases of prevention in chronic disease.  The CPGs include 
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an executive summary of 123 clinical practice recommendations which cover the spectrum of 
obesity management (Garvey et al., 2016).  The core recommendations for medical care of 
patients with obesity include three phases of chronic disease prevention and treatment (Garvey et 
al., 2016).  These three phases (primary, secondary, and tertiary interventions) should be the 
basis of the modality and intensity of obesity interventions (Garvey et al., 2016).   
 Three phases.  Phases of prevention include primary, secondary, and tertiary.  Primary 
prevention discusses ways to prevent the progress of overweight and obesity.  Secondary 
prevention considers ways to prevent further weight gain and weight-related complications in 
patients who are overweight or obese. Tertiary prevention examines ideas of treatment with 
weight-loss therapy to decrease weight-related complications and prevent advancement of 
disease (Garvey et al., 2016, see table 2).  
Table 2. 
Three phases of Prevention in Obesity as a Chronic Disease 
General Practices in Chronic Disease in Obesity 
Phase of Intervention Definition and Goals Methods of Prevention 
Primary Prevention o Preventatheadevelopmentaof 
overweight and obesity 
o Eliminateariskafactors 
 
o Educateatheapublic 
 
o Promote healthy eating and regular 
physicalaactivity 
 
Secondary Prevention o Prevent future weight gain and the 
developmentaofaweight-related 
complicationsainapatientsawith 
overweight or obesity 
o ScreenausingaBodyaMassaIndex 
(BMI) annually 
 
o Diagnose using BMI and evaluation 
for complications 
 
o Treatawithalifestyle/behavioral 
interventionawith/withoutaweight-
lossamedications 
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Tertiary Prevention o Treat with weight loss therapy to 
eliminateaweight-related 
complications  
 
o Prevent disease progression 
o Treatawithalifestyle/behavioral 
interventionsaplusaweight-loss 
medications 
 
o Considerabariatricasurgery 
 
Note: data from American Association of Clinical Endocrinologists and American College of Endocrinology clinical 
practice guidelines for comprehensive medical care of patients with obesity- Executive Summary, by Garvey et al. 
Retrieved from doi: 10.4158/EP161365.G (2016). 
 
  
BMI/Waist Circumference.  According to Garvey et al. and the AACE/ACE CPGs, 
body mass index (BMI) is the best anthropomorphic criteria for confirming an excess in 
adiposity (2016).  Diagnosing individuals as being overweight or obese in the clinical setting is 
based on BMI.  BMI is constructed using the formula weight in kilograms divided by height in 
meters squared (BMI= wt in kg/ht in m2).  Clinical evaluation must be considered when using 
BMI, taking in to account the age, gender, ethnicity, fluid status, and muscularity (Garvey et al., 
2016).  Individuals are considered overweight with a BMI of 25-29.9 kg/m2 and obese with a 
BMI of ≥ 30 kg/m2 (Garvey et al., 2016).   
Other methods of measure for adiposity such as air/water displacement or dual-energy x-
ray absorptiometry may be used if BMI and physical exam require further evaluation; cost, 
availability, and lack of validity do not support these methods (Garvey et al., 2016).  In addition 
to BMI, adiposity-related disease risk should be evaluated for every patient based on waist 
circumference (Garvey et al., 2016).  In the United States, indication of increased risk of disease 
are waist circumference ≥ 40 inches (≥ 102 cm) in men and ≥ 35 inches (≥ 88 cm) in women 
(Garvey et al., 2016, see table 3).   
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Table 3. 
Classification of Overweight and Obesity by BMI and Waist Circumference 
Classification of Overweight and Obesity by BMI and Waist Circumference  
per AACE/ACE CPG 
 
Classification BMI Waist 
BMI (kg/m2) Comorbidity 
Risk 
Waist Circumference and Comorbidity Risk 
   Men ≤40 in (102 cm) 
Women ≤35 in (88 cm) 
Men >40 in (102 cm) 
Women >35 in (88 cm) 
Underweight 
 
<18.5 Low   
Normal weight 
 
18.5-24.9 Average   
Overweight 
 
25-29.9 Increased Increased High 
Obese class I 
 
30-34.9 Moderate High Very High 
Obese class II 
 
35-39.9 Severe Very High Very High 
Obese class III 
 
≥40 Very Severe Extremely High Extremely High 
 
Abbreviations: BMI= body mass index; in= inches 
Note: data from American Association of Clinical Endocrinologists and American College of Endocrinology clinical 
practice guidelines for comprehensive medical care of patients with obesity- Executive Summary, by Garvey et al. 
Retrieved from doi: 10.4158/EP161365.G (2016). 
 
 Weight Related Complications & Therapeutic Benefits of Weight Loss.  After initial 
evaluation, and identification of weight-associated comorbidities there should be ongoing follow 
up to monitor for changes in adiposity and complications (Garvey et al., 2016).  In Table 4, the 
effect of weight loss on known comorbidities is outlined (see Table 4).   Weight loss can be an 
effective treatment of weight-related conditions with significant changes seen with just a 5% 
weight loss (Garvey et al., 2016).   
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Table 4. 
Treatment Goals Based on Diagnosis in the Medical Management of Patients with Obesity 
Treatment Goals Based on Diagnosis in the Medical Management  
of Patients with Obesity 
Tertiary Prevention 
Classification Anthropometric 
Component 
 
Clinical Component Weight Loss 
Goal (%) 
Clinical Goals 
Overweight or 
Obesity 
BMI ≥25 kg/m2 Metabolic syndrome 10% Prevention of T2DM 
 
  Prediabetes 10% Prevention of T2DM 
  T2DM 5% to ≥ 15% o Reduction in A1C 
o Reduction in number 
and/or doses of glucose 
lowering medications 
o Diabetes remission 
especially when diabetes 
duration is short 
 
  Dyslipidemia 5% to ≥ 15% o Lower triglycerides 
o Raise HDL-c 
o Lower non-HDL-c 
 
  Hypertension 5% to ≥ 15% o Lower systolic and 
diastolic BP 
o Reductions in number 
and/or doses of 
antihypertensive 
medications 
 
  Nonalcoholic 
fatty liver 
disease (NASH) 
Steatosis 5% or more Reduction in 
intrahepatocellular lipid 
 
Steatohepatitis 10% to 40% Reduction in 
inflammation and fibrosis 
 
  Polycystic ovary syndrome 5% to 15% or more o Ovulation 
o Regularization of 
menses 
o Reduced hirsutism 
o Enhanced insulin 
sensitivity 
o Reduced serum 
androgen levels 
 
  Female infertility 10% or more o Ovulation 
o Pregnancy and live 
birth 
 
  Male hypogonadism 5% to 10% or more Increase serum 
testosterone 
 
 
  Obstructive sleep apnea 7% to 11% or more o Improved 
symptomatology 
o Decreased apnea-
hypopnea index 
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  Asthma/reactive airway disease 7% to 8% or more o Improvement in 
forced expiratory 
volume at 1 second 
o Improved 
symptomatology  
 
  Osteoarthritis o ≥10% 
o 5% to 10% or 
more when 
coupled with 
exercise 
 
o Improvement in 
symptomatology  
o Increased function 
  Urinary Stress Incontinence 5% to 10% or more Reduced frequency of 
incontinence 
 
  Gastroesophageal reflux disease 10% or more Reduced symptom 
frequency and severity 
 
  Depression Uncertain o Reduction in 
depression 
symptomatology 
o Improvement in 
depression scores 
 
Abbreviations: A1C= hemoglobin A1C; BMI= body mass index; BP= blood pressure; HDL-c= high-density lipoprotein cholesterol; T2DM= 
type 2 diabetes mellitus. 
 
Note: data from American Association of Clinical Endocrinologists and American College of Endocrinology clinical 
practice guidelines for comprehensive medical care of patients with obesity- Executive Summary, by Garvey et al. 
Retrieved from doi: 10.4158/EP161365.G (2016). 
  
Lifestyle & Behavioral Therapy and Plan.  Along with evaluation, the AACE/ACE 
CPGs recommend a structured lifestyle intervention program designed for weight loss (2016).  
This should include healthy meal planning, physical activity, and behavioral interventions 
(Garvey et al., 2016).  According to Garvey et al., a reduced total energy (caloric) intake should 
be the main component for interventional weight-loss.  Meal plans should include a daily 
reduction of 500-750 kcal.  Dietary considerations can include the Mediterranean, DASH, low-
carb, low-fat, high protein, or vegetarian diets, and/or meal replacements.  Expertise from a 
dietician or health educator is optimal (Garvey et al., 2016).  The CPGs do not recommend one 
specific diet over another.  Diets that fit the individual’s lifestyle and likes/dislikes are important 
to take in to consideration to avoid barriers to weight loss.   
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 Reduction of sedentary lifestyle with an individualized program based on goals, 
preferences, and limitations should be discussed with an expert (trainer, coach, 
physical/occupational therapist) when possible (Garvey et al., 2016).  The AACE/ACE CPGs 
recommend aerobic physical activity progressing to >150 minutes/week 3 to 5 days per week 
along with resistance exercise involving major muscle groups 2 - 3 times/week (2016).  Given 
the current level of exercise reported by the vast majority of those who are obese, there should be 
a gradual progression to the recommended time of exercise. 
 Educational material on behavioral modification ought to be reviewed with a health 
educator, clinician, behaviorist, or clinical psychologist/psychiatrist (Garvey et al., 2016).  These 
materials should include helpful strategies in adhering to diet and exercise recommendations and 
self-monitoring of their weight loss strategies.  Patients are encouraged to set reasonable goals 
and be assisted in problem solving and coping as they engage in their weight loss journey.  
Support systems, such as group meetings or face-to-face sessions, along with identifying daily 
lifestyle barriers must be addressed (Garvey et al., 2016).   
 In addition to lifestyle therapy, pharmacotherapy can be considered in those who are 
overweight or obese specifically those with weight-related complications that can be improved 
by weight loss (Garvey et al., 2016).  It is important to note the recommended AACE/ACE CPGs 
(2016) state, “pharmacotherapy for overweight and obesity should be used only as an adjunct to 
lifestyle therapy and not alone” (p. 36).  For optimal weight-loss, clinicians need to consider 
patient specific medications considering efficacy, side effects, contraindications, medical history, 
and presence of weight-related complications (Garvey et al., 2016).  
 For individuals that have failed or have contraindications for pharmacotherapy, bariatric 
surgery may be an effective obesity treatment.  Patients with BMI ≥40 kg/m2 without coexisting 
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medical problems, patients with BMI ≥35 kg/m2 with one or more severe obesity-related 
complication (T2DM, hypertension, NASH, etc...), or patients with BMI of 30 to 34.9 kg/m2 with 
diabetes or metabolic syndrome may be considered for a bariatric surgery procedure (Garvey et 
al., 2016).  Surgery is not without risks nor without significant lifestyle changes. 
 Despite knowledge of diet and exercise, pharmacotherapy, and the advent of new 
technology (wearable fitness devices and wellness apps), obesity rates continue to escalate.  
Short-term treatment (3-6 months) with weight-loss medications has not been proven effective in 
producing long-term health benefits, so maintenance of weight loss is imperative but remains 
challenging (Garvey et al., 2016).  Even weight loss surgery has not been met with a complete 
reversal of obesity.  In those who have had surgery, not following the recommended diet can lead 
to weight gain not weight loss.  Without adequate motivation, solutions will be hard to 
implement (Emmett & Chandra, 2015). 
Theory 
The motivation to lose and maintain weight loss requires dedicated strategies.  A 
psychological theory of motivation, the Self-Determination Theory (SDT), along with coaching 
techniques can help overweight and obese individuals as they adopt healthy lifestyle habits and 
increase physical activity (Clarke, 2017).  The main idea of SDT centers around three basic 
needs that promote motivation: autonomy, competence, and relatedness (Clarke, 2017, see table 
5).   
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Table 5. 
Self-Determination Theory, basic needs  
Basic need that 
promotes 
motivation 
 
Definition Definition related to 
weight-loss 
Example 
Autonomy -When one acts on 
his/her own terms 
-Exploring one’s own 
perspectives on 
behaviors related to 
physical activity or 
weight loss 
interventions 
-If an individual 
physically cannot run 
or does not like to 
run, it is important 
that this is 
acknowledged and 
other alternatives for 
activities are explored 
 
Competence -When one feels 
confident they have 
the ability and 
resources to achieve a 
goal 
-Optimism, 
positivity, and 
providing positive 
feedback suggest 
one’s ability for 
successfully adopting 
and performing new 
behaviors 
 
-A lapse in behavior, 
such as failure to 
exercise, should be 
considered a 
temporary setback on 
the road to success 
Relatedness -Having substantial 
and supportive 
relationships (family, 
friends, healthcare 
providers, 
coaches/trainers) 
 
-Occurs with a 
support system, 
meeting new people 
and groups, and 
networking 
-A support group 
such as weight-
watchers that helps 
attain goals. 
Note: data adapted from multiple sources (Clarke, 2017; Patrick & Williams, 2012). 
 
Through autonomy (supporting and recognizing an individual’s lifestyle) this gives the 
individual an opportunity to express perspectives and concerns thus strengthening commitment 
and accountability for desired behavior change (Patrick & Williams, 2012).  By using skills such 
as problem solving and contingency planning, competence is enhanced, and the individual can 
effectively learn to cope with challenges, avoid setbacks, and continue his/her ongoing success 
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(Nag & Durand, 2016; Patrick & Williams, 2012).  Relatedness is reaching a goal with the help 
of a support system.  This is important in the sustainability of behavior change.   
According to a systematic literature review completed by Teixeira et al. (2012), the most 
important skill correlated with successful weight loss outcomes was the use of self-regulation.  
Self-regulation includes monitoring weight and food choices, goal setting and planning 
(Teixeira, Carraca, Markland, Silva, & Ryan, 2012).  Based on the CPGs, after education, 
motivation, and attempting lifestyle/behavior change, pharmacologic options should be 
incorporated.   
Pharmacologic Weight Management 
History of Weight Loss Medications 
Medications for weight management has been associated with significant negative effects 
and perhaps it is this history that impedes providers from exploring the newer drugs. The first 
weight loss medications were introduced in the 1900s.  These anti-obesity medications involved 
increasing basal metabolic rates (BMR) (Adan, 2013).  Thyroid hormones and Tenuate 
(dinitrophenol) were the first prescription drugs for weight loss, but the increase in BMR caused 
overheating and death (Adan, 2013).   
Later, amphetamines, introduced in the 1930s, looked promising for weight loss but were 
found to be addictive and produced cardiovascular side effects (Adan, 2013).  However, in 1992, 
fenfluramine was combined with phentermine (Fen-phen) and gained international attention with 
efficacy of up to 10% bodyweight (Adan, 2013).  Unfortunately, this medication combo was 
discontinued after notable causes of pulmonary hypertension (Adan, 2013).  In 1997, the FDA 
approved sibutramine, but due to cardiovascular changes leading to cardiovascular events (stroke 
and myocardial infarction) the medication was discontinued (Adan, 2013).   
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Subsequently, in 1997 Orlistat was introduced; however, side effects such as fecal 
incontinence and oily stools led to poor compliance (Adan, 2013).  Excitingly, in 2012, Qsymia 
(phentermine plus topiramate) and Contrave (bupropion plus naltrexone), both polytherapies, and 
Belviq (lorcaserin) were added to the FDA approval list and show great promise for obesity 
treatment (Adan, 2013).  Saxenda (the newest medication) received approval in 2014 and has 
supportive long-term data for meaningful weight loss, shows great efficacy, but is cost 
constraining (Velazquez & Apovian, 2018).     
Current Prescribing Practices 
Nationally, obesity is a chronic disease that affects over 78 million adults, yet only 2% of 
all eligible obese adults receive pharmacotherapy from a provider (Mehta et al., 2012; Velazquez 
& Apovian, 2018).  According to a Medscape survey of 1282 healthcare providers, only 58% 
prescribed weight loss medications to those who were overweight/obese (Garvey & Wiebe, 
2018).  Currently in the U.S. there are eight Food and Drug Administration (FDA)-approved 
drugs used to help aid in weight loss (Velazquez & Apovian, 2018).   
Each medication impacts the body in different ways.  Pharmacologic interventions 
include those that act centrally as noradrenergic agents, medications that interfere with fat 
absorption, and an analog of human glucagon-like peptide-1 (GLP-1) which suppresses appetite.  
Three of the most common medications within these categories, Adipex, Contrave, and Saxenda, 
were evaluated in their efficacy for weight loss. 
In 1959, Adipex (phentermine), another amphetamine, was introduced (Adan, 2013).  
Adipex remains the most commonly prescribed and well researched today due to affordability 
and limited side effects (Adan, 2013; Velazquez & Apovian, 2018).  Adipex (phentermine), 
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Tenuate (diethylpropion), Bontril (phendimetrazine), and Didrex (benzphetamine), act as 
appetite suppressants by affecting the central nervous system (Yanovski & Yanovski, 2014).  
Adipex (phentermine) is indicated for those with a BMI of ≥30 kg/m2 or BMI ≥27 kg/m2 
with comorbidities (Phentermine (Rx), 2016).  In the United States, an estimated 25.3 million 
prescriptions were dispensed between 2008-2011 (Velazquez & Apovian, 2018; Yanovski & 
Yanovski, 2014).  This very affordable medication has been proven to result in clinically 
significant weight loss in a short time (12 weeks) with adjunctive lifestyle modification 
(Velazquez & Apovian, 2018).   
Between 2008-2011, according to the National Institute of Health public access, patients 
using 15-30 mg/d Adipex had a mean total weight loss of 6.3 kg based on a meta-analysis of six 
studies over 2 to 24 weeks (Yanovski & Yanovski, 2014).  Combination therapy with low doses 
of Adipex have been approved for long-term obesity management.  While Adipex alone has been 
prescribed long term without evidence of serious side effects and low levels of potential 
addiction, long-term studies are lacking on monotherapy effects and cardiovascular risk; hence, 
more long-term studies are needed (Yanovski & Yanovski, 2014).   
Orlistat, a gastrointestinal lipase inhibitor, defers fat absorption by blocking some of the 
fat you eat (Yanovski & Yanovski, 2014).  The side effect profile is unpalatable which has 
decreased its favorability among patients.  A version of Orlistat was reformulated to be over the 
counter (Alli) which unfortunately did not improve its acceptability (Yanovski & Yanovski, 
2014).   
Belviq (Lorcaserin), a serotonin receptor activator, works as an appetite suppressant by 
affecting chemical signals in the brain that control appetite (Yanovski & Yanovski, 2014).   Two 
combination medications, Qsymia (phentermine plus topiramate-ER) and Contrave (naltrexone 
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plus bupropion-SR), work together to suppress appetite (Yanovski & Yanovski, 2014).  
Regarding Qsymia, phentermine is a noradrenergic agonist, and topiramate ER acts on GABA 
receptors leading to appetite suppression (Velazquez & Apovian, 2018).  For Contrave, the 
mechanism of action for buproprion SR is the inhibition of dopamine and norepinephrine 
reuptake; naltrexone acts to antagonize the feedback loop that limits buproprion’s anorexic 
effects, thus the drugs work together to produce appetite suppression (Velazquez & Apovian, 
2018).  Interestingly, Contrave is a combination of naltrexone and bupropion; naltrexone is 
approved to treat alcohol and opioid dependence and bupropion is approved to treat depression 
and seasonal affective disorder and as an aid to smoking cessation treatment (FDA, 2014). 
The FDA approved Contrave for long-term use in adults with a BMI of ≥30 kg/m2 or 
adults with a BMI ≥27 kg/m2 who have at least one weight-related condition such as high blood 
pressure, type 2 diabetes, or high cholesterol (FDA, 2014).  The effectiveness of Contrave was 
evaluated in multiple clinical trials.  In one trial, 42% of patients treated with Contrave lost at 
least 5% of their body weight compared with 17% of patients treated with placebo (FDA, 2014). 
Approved in 2014 by the FDA, Saxenda (liraglutide), a GLP-1 receptor agonist, is the 
only long-acting daily injectable therapy approved for medical weight loss (Curry, 2017; Isaacs 
et al., 2016).  Saxenda (liraglutide) is the newest weight loss medication on the market and is an 
analog of human glucagon-like peptide-1 (GLP-1) (Velazquez & Apovian, 2018).  Saxenda 
mimics the endogenous GLP-1 hormone (Velazquez & Apovian, 2018).  This hormone is 
released from the small intestines producing appetite suppression and increases the release of 
insulin from the pancreas when glucose is present (Velazquez & Apovian, 2018).   
Interestingly, recent research has shown medications used for glycemic control in those 
with type 2 diabetes (T2DM), known as GLP-1 receptor agonists, have produced weight loss 
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effects in patients with or without diabetes (Isaacs, Prasad-Reddy, & Srivastava, 2016).  Saxenda 
has proven to be effective in moderate weight loss. It has been shown to decrease systolic blood 
pressure and reduce lipid parameters with minimal side effects including gastrointestinal 
symptoms such as nausea, vomiting, and diarrhea (Abramowicz et al., 2016; Curry, 2017; Scott, 
2015).   
A one-year study showed an average of 5.6% decrease in total body weight in those 
treated with Saxenda (Garvey et al., 2016).  One well-designed 56-week phase III trial showed 
Saxenda was associated with significant (p< .0001) waist circumference and BMI reductions 
from baseline to 56 weeks (Bode et al., 2014).  Waist circumference was reduced by 4.7 cm in 
the Saxenda group compared to 1.2 cm in the placebo group (Bode et al., 2014).  Unfortunately, 
this is the most expensive antiobesity medication on the market at approximately $1100 per 
month (Curry, 2017).  
Cost of Medication 
The Affordable Care Act (ACA) covers obesity screenings and counseling (Wilson, Kyle, 
Nadglowski, & Stanford, 2017).  However, obesity treatments, such as medical weight 
management programs and medications, are not considered essential benefits and many states 
provide minimal or no coverage for these treatments (Wilson et al., 2017; Yang & Pomeranz, 
2015).  One study, among 136 marketplace health insurance plans, showed merely 11% had 
some coverage for drugs (such as Adipex, Contrave, and Saxenda) in only 9 states (Gomez & 
Stanford, 2018).  Medicare policy strictly excludes drug therapy for obesity treatment, and only 
seven states have Medicaid drug coverage for antiobesity medications (Gomez & Stanford, 
2018).  Ironically, federal government employees (consisting of roughly 2.7 million 
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beneficiaries) have health benefit plans that are not allowed to exclude coverage of antiobesity 
medications (Gomez & Stanford, 2018).   
Another study found that obese patients stay on medication longer, see his/her PCP more 
often, and lose more weight with adequate medication reimbursement (Baum et al., 2015).  With 
the proven clinical effects of pharmacologic obesity management and reducing weight-related 
complications, this information indicates a need for broader coverage of pharmacotherapy 
(Gomez & Stanford, 2018).  Each FDA approved medication included in this study is listed 
below along with the mechanism of action, side effects, and overall cost (see table 6).  Clearly, 
one can see that Adipex is the most cost effective.   
Table 6. 
 
Medication Overview 
 
Drug/dose Mechanism 
of action 
Side effects Contraindicat
ions 
Cost/mon
th (some 
not 
covered 
by 
insurance 
plans) 
Efficacy 
in % of 
body 
weight 
∆ 
waist 
circum
ferenc
e  
Adipex 
(phentermine) 
15-37.5 mg 
oral 
Nonadrenalin 
releaser, 
appetite 
suppressant 
Insomnia, 
elevation in 
heart rate, dry 
mouth, taste 
alterations, 
dizziness, 
tremors, 
headache, 
diarrhea, 
constipation, 
vomiting, 
gastrointestina
l distress, 
anxiety, and 
restlessness 
 
Not for 
patients with 
advanced 
cardiovascular 
disease, 
moderate to 
severe 
hypertension, 
hyperthyroidis
m, glaucoma, 
and agitate 
states 
$6-45  -5-10% -3-4.5 
inches 
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Contrave 
(bupropion 
with 
naltrexone) 
8 mg/90 mg 
oral 
 
Noradrenalin
/dopamine 
reuptake 
inhibitor and 
opioid 
receptor 
antagonist 
Cardiovascula
r side effects 
(monitor for 
increase heart 
rate and blood 
pressure), 
nausea, 
vomiting, 
diarrhea, 
headache, 
dizziness, 
insomnia 
Not for 
patients with 
uncontrolled 
hypertension, 
chronic opioid 
use, seizure 
disorder, 
anorexia or 
bulimia, during 
withdrawal 
from alcohol, 
barbituates, 
benzodiazepine
s, and 
antiepileptic 
drugs 
$90-255 -5-10% -2-4 
inches 
Liraglutide 
(Saxenda) 3mg 
SQ 
GLP-1 
receptor 
agonist at 
satiety center 
of brain, 
resulting in 
slowed 
gastric 
emptying 
Nausea, 
vomiting, 
gastrointestina
l symptoms, 
possible 
hypoglycemia
, abdominal 
pain, 
headache, 
fatigue, 
increased 
lipase 
 
Potential 
serious 
toxicities: 
pancreatitis, 
medullary 
thyroid 
carcinoma 
Not for 
patients with 
personal or 
family history 
of medullary 
thyroid 
carcinoma or 
Multiple 
Endocrine 
Neoplasia 
syndrome type 
2. Should not 
be used with 
insulin or other 
GLP-1 
agonists. 
 
$1,150 Loss of 
3.6-5 
kgs 
4.7 cm 
 
**All antiobesity drugs are contraindicated in pregnancy. 
 
Note: Data adapted from multiple sources, (Adan, 2013; Fujioka & Braverman-Panza, 2016; 
Gadde et al., 2018; Goodrx, 2017; Isaacs et al., 2016; Scott, 2015; Yanovski & Yanovski, 2014). 
 
Although lifestyle/behavioral interventions are primary in management, most overweight 
or obese individuals require adjunctive pharmacotherapy to achieve clinically significant weight 
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loss (≥ 5% bodyweight reduction) (Scott, 2015).  The initial weight loss goal with behavioral 
changes and pharmacotherapy is 5% or more of total body weight (Velazquez & Apovian, 2018).  
This weight loss has proven sufficient in reduction of health risks such as hypertension, T2DM, 
and hyperlipidemia (Velazquez & Apovian, 2018).  According to Velazquez and Apovian 
(2018), “the objective for using pharmacotherapy to manage obesity is to amplify patient 
adherence to lifestyle changes and to overcome the biological adaptations that occur with weight 
loss” (p. 107).  The quality improvement project proposed in this paper will evaluate the impact 
of medications Adipex, Adipex plus Contrave, and Adipex plus Saxenda and their effectiveness 
on BMI, weight loss, and waist circumference. 
Purpose 
Project Aims  
AIM 1: To determine the effectiveness of Adipex on BMI, weight loss, and waist circumference 
in patients at a rural weight loss clinic. 
1. Was BMI, weight, and waist circumference effected in Adipex patients? 
2. Did Adipex have barriers (side effects) that prevented medication adherence? 
AIM 2: To determine the effectiveness of Adipex plus Contrave on BMI, weight loss, and waist 
circumference in patients at a rural weight loss clinic. 
1. Was BMI, weight, and waist circumference effected in Adipex plus Contrave patients? 
2. Did Adipex plus Contrave have barriers (side effects) that prevented medication 
adherence? 
AIM 3: To determine the effectiveness of Adipex plus Saxenda on BMI, weight loss, and waist 
circumference in patients at a rural weight loss clinic. 
1. Was BMI, weight, and waist circumference effected in Adipex plus Saxenda patients? 
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2. Did Adipex plus Saxenda have barriers (side effects) that prevented medication 
adherence? 
Objectives: 
A. Examine a group of 30-100 patients at a rural weight loss clinic taking weight loss 
medications from September 2014- September 2017. 
a. Each patient was followed for an initial visit, 2-month visit, 3-month visit, and 6-
month visit. 
i. Visit 1- Gather baseline data and medication were prescribed 
1. Initial measurements (BMI, weight, waist circumference) 
2. Demographic information, co-morbidities, smoking and alcohol 
use  
3. Diet and exercise plan 
ii. 2-month visit 
1. Measurements (BMI, weight, waist circumference) 
2. Counseling on diet and exercise adherence 
3. Side effect discussion 
iii. 3-month visit 
1. Measurements (BMI, weight, waist circumference) 
2. Counseling on diet and exercise adherence 
3. Side effect discussion 
iv. 6-month visit, has patient experienced decreased BMI, weight loss, or 
waist circumference? 
1. Measurements (BMI, weight, waist circumference) 
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2. Counseling on diet and exercise adherence 
3. Side effect discussion 
B. Was there any change in metabolic profile between visits? 
a. Changes in measurements (BMI, weight, waist circumference) 
Methods 
This project was a single-center retrospective study of the comparison of three different 
groups taking Adipex, Adipex plus Contrave, and Apidex plus Saxenda and the effect on weight 
loss, BMI, and waist circumference.  This project also compared the medications on 
comorbidities and demographics.  The sample consisted of 84 patients from a rural weight loss 
clinic evaluated from September 2014 to September 2017. 
Setting 
The rural weight loss clinic is a group that specializes in weight loss evaluation, 
treatment, and management.  The clinic is owned by a Family Nurse Practitioner who is the 
primary provider in the clinic.  Improving the overall health of individuals that struggle with 
being overweight and obese is accomplished within this clinic by educating, assessing, 
encouraging, motivating, and providing supportive therapy.  The rural weight loss clinic provides 
a medically-supervised weight loss program for people who would like to improve their health 
by losing weight.  The nurse practitioner uses the dual approach of lifestyle modification and 
anti-obesity medications.  
The clinic has been open since 2010. The provider has not completed a thorough 
assessment of their weight loss outcomes and has requested a chart review. In this setting, the 
effectiveness of weight loss medications in the treatment of obesity has not been documented. 
This project was focused on reviewing patient data who have been prescribed Adipex, Adipex 
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plus Contrave, and Adipex plus Saxenda, and compared the effectiveness of each.  Evaluation of 
effectiveness was based on Body mass index kg/m2 (BMI), weight in pounds (lbs), and waist 
circumference (inches).   
Sample 
For this project, three different groups were evaluated.  All selected participants were 
rural weight loss clinic patients.  The review was conducted between September 2014- 
September 2017.  The groups consisted of 34 patients that have taken Adipex, 30 patients that 
have taken Adipex plus Contrave, and 20 patients that have taken Adipex plus Saxenda to lose 
weight. 
 Inclusion Criteria.  Rural weight loss clinic patients only with a BMI of ≥ 27 kg/m2 
(overweight) with comorbidities present or a BMI of ≥ 30 kg/m2 (obese) with or without 
comorbidities present (such as hypertension, dyslipidemia, type 2 diabetes).  All patients were 
over the age of 18 and prescribed a weight loss medication.  Adherence to a diet and exercise 
regimen was required.  The regimen was not prescriptive and could include participation in 
group weight loss programs (i.e. Jenny Craig or Weight Watchers).  
 Exclusion Criteria.  Patients who missed a scheduled monthly appointment or patients 
who had to change medication during course of treatment.   
Measurements 
The following measures were extracted from the paper patient documented medical records 
to provide an analysis for objectives (see table 7). 
1. Body Mass Index kg/m2 (BMI), weight (lbs), and waist circumference (inches): BMI, 
weight in pounds, and waist circumference in inches before and after treatment was 
gathered to determine weight loss therapy effectiveness. 
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2. Medication reconciliation document: The medication reconciliation document was used 
to determine which patients were prescribed Adipex, Adipex plus Contrave, and Adipex 
plus Saxenda. 
3. Metabolic data: An initial assessment was conducted for each patient to identify vital 
signs and co-morbidities. 
4. Demographic data: Demographic data included gender (male vs. female), age (in years), 
ethnicity, and lifestyle habits (diet, exercise, smoking, ETOH). 
 
Table 7. 
 
Study Measures 
 
Outcome Measures Level of Measure Time of Measure Data 
Collection 
Demographic  
Gender Male vs female Nominal Frequencies, chi-
square 
Medical records 
Ethnicity White, black, 
Hispanic, 
Indian, native 
American, 
middle eastern, 
mixed race, 
Asian, other 
Nominal Frequencies, chi-
square 
Medical records 
Age Age in years Interval/Ratio Frequencies, chi-
square 
Medical records 
Program Information 
Medical 
Reconciliation 
document 
Names of 
medications 
prescribed to 
patient 
Nominal Frequencies, chi-
square 
Medical records 
Vital signs 
(BP, HR) 
Blood Pressure- 
mmHg 
Heart rate- 
beats/min 
 
Interval/Ratio Means (SD), t-test Medical records 
Co-morbidities Patient 
documented 
history 
Nominal Frequencies, chi-
square 
Medical records 
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Lifestyle 
habits (diet, 
exercise, 
smoking, 
ETOH, drug 
use) 
Patient 
documented 
history 
Nominal Frequencies, chi-
square 
Medical records 
BMI kg/m2 Interval/Ratio Means (SD), one-
way ANOVA 
Medical records 
Weight Pounds (lbs) Interval/Ration Means (SD), t-test Medical records 
Waist 
Circumference 
Inches Interval/Ration Means (SD), t-test Medical records 
Side effects Patient records Nominal Frequencies, chi-
square 
Medical records 
 
Data Collection 
 Approvals from the University of Kentucky Institutional Review Board (IRB) were 
obtained prior to data collection.  This project was based on a retrospective chart review.  Data 
collection was completed at the rural weight loss clinic.  The clinic used paper documentation 
and each patient file was selected based on inclusion and exclusion parameters.  Data collected 
was based on the table above including gender, ethnicity, age, medications, vital signs, co-
morbidities, lifestyle habits, BMI, weight, waist circumference, and side effects.  After data was 
collected from patient records, using no patient identifiers, data was transferred to an excel 
spreadsheet.  
Data Analysis 
Descriptive statistics such as mean and standard deviation or frequency distributions were 
used to summarize demographic data, medications, vitals, co-morbidities, lifestyle habits, and 
side effects.  The chi-squared test of association (or Fisher’s exact test, as appropriate) or the 
two-sampled t-test was used to test for group differences in demographic characteristics.  One-
way ANOVA tests were used to test for group differences in change in BMI, weight, and waist 
circumference (from baseline to each follow up appointment).  A post-hoc analysis directed any 
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significant findings for ANOVA to test which group means differed.  All data analysis was 
conducted using SPSS version 24 with an alpha level of .05. 
Results 
Sample Characteristics 
A total of 250 patient charts were reviewed and 84 were selected based on the inclusion 
criteria for the retrospective analysis.  Of these 84 selected, 34 patients had taken Adipex, 30 had 
taken Adipex + Contrave, and 20 had taken Adipex + Saxenda.  Each patient had taken 
medication over a 6-month period with visits at baseline, 2-months, 3-months, and 6-months.     
The baseline characteristics of these patients were individually assessed.  The average 
age of participants was 45 years of age (range, 19-67 years of age, see table 1); 87% of 
participants were female.  The overall analysis consisted of 99% Caucasian participants and 1% 
African American participants.  The mean BMI of patients at baseline was 36 kg/m2 (range, 25-
54 kg/m2), average weight at baseline was 218 lbs (range, 144-358 lbs), and average waist 
circumference at baseline was 40.6 inches (range, 30-60 inches).  There were no differences in 
baseline demographics or baseline physical characteristics between the three groups which 
demonstrated an even starting point.  
Overall comorbidities were assessed with majority consisting of hypertension (37%), 
prediabetes or diabetes (20%), and GERD (10%).  Seventeen percent (17%) reported a family 
history of heart disease, 7% family history of diabetes, and 4% family history of cancer.  Overall 
lifestyle habits examined alcohol use and smoking with average of 15% of patients consuming 
alcohol socially and 5% current smokers.   
Compliance of a diet and exercise regimen was assessed for each group at each visit.  
Those taking Adipex had 12% (n=4) noncompliance with a diet and exercise regimen; only half 
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of those noncompliant still lost weight. Adipex + Contrave users were found to have a 23% 
(n=7) noncompliance rate with diet and exercise; of those, 86% (n=6) still experienced weight 
loss.  Patients taking Adipex + Saxenda had a 15% (n=3) noncompliance rate with diet and 
exercise; all still experienced weight loss. 
 Side effects for each group were evaluated.  Twenty nine percent (n=10) of Adipex users 
reported side effects consisting of GERD, edema, headaches, fatigue, hair loss, constipation, or 
back pain.  Of those 29%, less than one percent (n=2) claimed these undesirable side effects 
made them noncompliant with medication adherence.  Those noncompliant with medications 
were also noncompliant with diet and exercise.  None experienced positive changes in weight 
loss, BMI, or waist circumference when they did not adhere to the medication or a diet and 
exercise regimen.  
The other groups had combined prescribed medications. The Adipex + Contrave group 
reported 15% (n=5) experienced side effects such as diarrhea, constipation, and fatigue.  This 
group had a 10% (n=3) noncompliance with medication regimen.  Side effects were not a factor 
in medication adherence for this group.  Those that did not take medication as prescribed still 
adhered to a diet and exercise regimen and experienced a reduction in weight, BMI, and waist 
circumference.   
Adipex + Saxenda users reported 17% (n=5) that experienced side effects such as fatigue, 
dizziness, constipation, or diarrhea.  Of those with side effects, 10% (n= 2) were noncompliant 
with medication adherence.  These patients did not maintain a diet and exercise regimen, but still 
experienced reduction in BMI, weight, and waist circumference, although minimal. 
Overall, 32% of patients reported using a weight loss app on his/her smartphone, 63% 
reported following a low calorie, high protein diet, and 89% reported some form of 
32 
 
cardiovascular exercise at least twice a week.  Overall mean baseline vital signs were 113 
systolic and 74 diastolic (mmHg), 88 heart rate, 17 respiratory rate (breaths/min), 96.7º 
temperature (ºFahrenheit), and 98% oxygen saturation (room air).  No significant vital sign 
changes or outliers were noted throughout the project. 
Findings 
Intragroup Data 
BMI.  Individual assessment of BMI for each group was evaluated using a paired t-test 
(see figure 1).  Adipex users experienced an average of 2.7 kg/m2 reduction in BMI (p= .000).  
Adipex + Contrave patients had a mean 2.5 kg/m2 reduction in BMI (p=.000).  The Adipex + 
Saxenda group resulted in an average loss of 2.7 kg/m2 in BMI (p= .001).  Each group had a 
statistically significant reduction in BMI. 
 
Figure 1. BMI Loss per Individual Medication 
 
Note: Each group had a statistically significant BMI reduction. 
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Weight.  Comparing individual drugs and the effect on weight was conducted using a 
paired t-test (see figure 2).  Adipex users experienced an average of 16.3 pounds lost (p= .000).  
Adipex + Contrave patients had a weight loss of 15 pounds (p=.000).  The Adipex + Saxenda 
group resulted in an average loss of 21 pounds (p= .000).  Each group had a statistically 
significant reduction in weight. 
 
Figure 2. Weight Loss per Individual Medication 
 
Note: Each group had a statistically significant weight loss. 
 
Waist Circumference.  Individual comparison of each drug and the effect on waist 
circumference was conducted using a paired t-test (see figure 3).  Adipex users experienced a 
mean of 3.1 inches lost (p= .000).  Adipex + Contrave patients had a waist circumference loss of 
3.8 inches (p=.000).  The Adipex + Saxenda group resulted in an average loss of 4.8 inches (p= 
.000).  Each group had a statistically significant reduction in weight. 
 
170
180
190
200
210
220
230
Adipex Adipex + Contrave Adipex + Saxenda
W
ei
gh
t 
(l
b
s)
Medications
Weight baseline Weight 6-months
34 
 
Figure 3. Waist Circumference Loss per Individual Medication 
 
Note: Each group had a statistically significant loss in waist circumference. 
 
Intergroup Comparison.  A one-way ANOVA performed between the three groups for 
comparison showed no statistical significance in baseline data on age, weight, BMI, and waist 
circumference.  Using a one-way ANOVA, the three groups were compared to note differences 
in weight, BMI, and waist circumference from baseline to 2-months, baseline to 3-months, and 
baseline to 6 months.  No statistical difference was found in BMI (base – 2 mo, p=.506; base – 3 
mo, p=.853; base – 6 mo, p=.961; see figure 4) or weight (base – 2 mo, p=.681; base – 3 mo, 
p=.451; base – 6 mo, p=.314; see figure 5).  The one-way ANOVA comparing the three groups 
in change in waist circumference from baseline to 3 months was significant (p=.027; see figure 
6).  In the post hoc analysis, Adipex + Saxenda users had a significantly higher waist 
circumference difference compared to Adipex (p=.01) and Adipex + Contrave users (p=.03). 
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Figure 4.  Average BMI Loss Comparing Groups 
 
Note: there were no statistical differences in BMI loss between groups. 
 
 
Figure 5.  Average Weight Loss Comparing Groups 
 
Note: there was no statistical difference in weight loss between groups. 
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Figure 6.  Average Waist Circumference Loss Comparing Groups 
 
Note: Statistical significance was noted from baseline to 3-months in waist circumference loss. 
 
Between the three groups, there was no statistical significance in the percentage of weight 
loss. On average, all groups experienced clinically significant weight loss (>5% total weight loss 
percentage).  Patients taking Adipex experienced 7.2% weight loss percentage (range, -3.5 to 
16%, see figure 7).  Patients taking Adipex + Contrave also averaged a weight loss percentage of 
7.2% (range, -7.5 to 16%).  Those taking Adipex + Saxenda averaged the most weight loss 
percentage of 9.1% (range, 2 to 22%).   
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Figure 7.  Average Weight Loss Percentage over 6 months 
 
Note: there was no statistical difference in weight loss percentage between groups.  
 
Discussion 
 The growing emphasis placed on weight loss has spurred the opening of dedicated clinics 
to assist people with their weight loss journey.  Evaluating results in patients who attend such a 
clinic must be viewed under the lens of self-selection.  These patients elect to seek out treatment 
outside of just diet and exercise.  Many providers in the primary care setting only decide to initiate 
weight loss medications after a patient has trialed a recommended diet and exercise plan (Garvey 
& Wiebe, 2018).  While patients may be trialing diet and exercise regimens, many become 
discouraged by lack of fast weight loss and seek pharmacotherapy at weight loss clinics 
(Heymsfield & Wadden, 2017).   
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Demographics 
Nationally, in 2014, those between the age of 40-59 years were more likely to be obese 
(41%) thus correlating with the average age in this study of 45 years (State of Obesity, 2017).  
Ethnically, this project was not diverse.  According to studies, African American women report 
taking pride and having a positive body image, while white women expressed self-depreciation 
and depression (Chugh, Friedman, Clemow, & Ferrante, 2013).  This information concurred with 
the data of primarily white females for this project. 
Age, gender, and race were not evaluated between groups for the effectiveness of 
medications due to the small and unvaried sample size.  In completing the review of literature, no 
evidence was noted that there is a difference between ethnicities, gender, or age and the 
effectiveness of weight loss medications.  Though, socioeconomic status was not addressed in 
this project, it would have offered insight to the burden of cost on taking prescription weight loss 
medications.  Of note, many of the patients evaluated in this project did have insurance coverage. 
Whether the insurance covered the medications prescribed could not be determined. 
Medications 
 According to literature, numerous studies have shown greater weight loss outcomes with 
combination therapy as opposed to monotherapy (Velasquez & Apovian, 2018).  This retrospective 
analysis did not statistically support those findings.  However, this could be due to the small sample 
size, noncompliance, or lack of proper medication choice for the patient as everybody responds 
differently.   
Adipex. Per discussion with the provider of the weight loss clinic, patients often present 
requesting Adipex. They have heard of its effectiveness and affordability.  Adipex is the cheapest 
weight loss medication available with minimal side effects (Adan, 2013).  While the side effect 
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profile was largest for this group (29%), side effects were not serious and did not lead to significant 
medication noncompliance.  For over two decades, this medication has been prescribed in the U.S. 
without serious side effects and low addiction potential (Velasquez & Apovian, 2018).  Findings 
in this retrospective analysis support its effectiveness making this medication a feasible first line 
option for weight loss management. 
Adipex + Contrave.  Contrave has demonstrated effectiveness when used alone. There 
was no evidence to support adding Adipex to Contrave. Per comparison with other studies, 
common side effects such as gastrointestinal upset correlated with the project findings (Velasquez 
& Apovian, 2018).  With no evidence found in this project to suggest Adipex and Contrave had 
more benefits than Adipex alone, it is the addition side effect profile that must be considered when 
adding another drug, although only 15% experienced minimal side effects in this project.   
Adipex + Saxenda.  Adipex + Saxenda demonstrated no added benefit when combined 
for weight loss.  Only 17% experienced minimal side effects, and those noncompliant with diet 
and exercise still experienced weight loss. Findings of weight loss while using medication only 
correlates with literature reviews (Velasquez & Apovian, 2018).   
A Statistical significant difference in waist circumference was noted between the groups.  
From baseline to 3-month data point, Adipex + Saxenda users had the greatest reduction.  This 
finding remains curious as there was no real difference in the amount of weight lost between 
groups.  One might surmise that either waist circumference was not measured properly, or body 
shape could influence area of weight loss.  Saxenda is a GLP-1 receptor agonist creating insulin 
sensitivity and targets adiposity in the abdominal region; which could explain waist reduction 
(Velazquez & Apovian, 2018).  Waist circumference has not been adopted as a standard for 
evaluating for obesity because of the variability in measurement (Ma et al., 2013). 
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Comorbidities.  The only comorbidity that was evaluated was hypertension.  In this 
sample, there was no evidence of hypertension.  At baseline, none were hypertensive (even the 
ones reporting hypertension in medical history) which could indicate they were already receiving 
treatment.  Given that this clinic was still using paper charts, a complete medication list was not 
readily found.  Laboratory values were not included or assessed to follow improvements in 
hyperlipidemia, thyroid issues, diabetes, or other comorbidites.  
Interestingly, in this analysis there was only 3% depression/anxiety comorbidities 
reported overall.  It was difficult to interpret this finding given the medication list was not 
complete.  Per research findings, psychological symptoms such as anxiety and depression show a 
bidirectional relationship with obesity (Collins et al, 2016).  Given the data, a higher percentage 
of patients in this analysis were expected to report depression and anxiety as a comorbidity.  
Sample size and ongoing treatment could have influenced this finding. 
Medication Compliance.  Medication, diet, and exercise compliance were assessed during 
this retrospective project. According to the 2018 Medscape study by Garvey and Wiebe, providers 
preferred the patient to focus on diet, exercise, and behavioral therapy because they were 
concerned about safety and side effects of mediations.  Thirty two percent of those surveyed 
admitted they did not have enough knowledge about weight loss medications (Garvey & Wiebe, 
2018).  Results from this project determined side effects were minimal and were not a deterrent 
for adherence to medication compliance.  Therefore, there is a need for provider education on side 
effects and safety of weight loss medications.  
Activities.  Diet tracking apps, cardiovascular exercise, and low calorie high protein diets 
are recommended and expected at the rural weight loss clinic.  Each patient is educated on these 
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aids and is strongly informed that this is a part of the weight loss plan.  For good outcomes, none 
of these three things can be excluded.   
Compliance with cardiovascular exercise at 89% was surprising as finding time and 
motivation to exercise is a barrier (Heymsfeld & Wadden, 2017).  Exercise compliance was 
unexpected due to Kentucky’s limited rate in physical activity of 30% (Walsh et al., 2016).  It is 
important to note this is a self-selected group independently seeking weight loss, which indicates 
readiness for change; therefore, they are more motivated to adopt these lifestyle changes. 
Implications 
Primary care providers have a great responsibility in obesity education and management.  
Clinical Practice Guidelines provide vast information on obesity screening and management as 
well as comorbidity assessments.  Evaluation of BMI should be evaluated at least annually for 
each patient, screening for overweight and obesity, and then treating per guideline 
recommendations.  
Based on the CPGs, PCPs should be addressing and treating overweight individuals as a 
precursor and work towards preventing the disease of obesity.  Similar to hypertension, 
education and options for diet and exercise should be presented to the patient well before the 
patient nears the overweight BMI window.  The progression to obesity and other comorbidities 
can be offset with dedicated interventions.  
Any environmental characteristic that acts as barrier to healthy body weight is considered 
obesogenic (Lakerveld, Mackenbach, Rutter, & Brug, 2018).  Poor diet and sedentary lifestyle 
are modifiable factors that are directly linked to our obesogenic environment (Lakerveld et al., 
2018).  Our surrounding such as availability of food, food traditions, institutional rules (school 
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food rules), and food prices effect our diet and lifestyle decisions daily (Lakerveld et al., 2018).  
Ways to avoid these barriers should be addressed with patients.   
The difficulties of achieving and maintaining weight loss is a significant challenge where 
all barriers should be addressed (Puhl et al., 2017).  Addressing barriers such as bias, access to 
care, socioeconomic factors, cost, and lifestyle/behavior should be included in evaluation and 
planning of overweight and obese patients. With this knowledge, we need to start looking at 
novel interventions such as telemedicine.  Telemedicine, health groups, and trainers should be 
included in aiding weight loss if possible (Alencar et al., 2017).  Mobile phone-based health 
coaching and weekly video conferencing have been effective in clinically significant weight loss 
(Alencar et al., 2017).  Use of smartphone apps and wearable fitness devices should be 
encouraged if the individual views it as necessary to aid in weight loss/management. 
More importantly, PCPs need to step up and embrace actively helping their patients lose 
weight.  One might wonder why we need dedicated weight loss clinics where diet, exercise, and 
weight loss medications are sought out. In essence, this can create silos of patient care where 
coordination of care is impeded and is more costly for this patient.  For example, a patient must 
pay a copay every time he/she goes to the PCP and weight loss clinic.  What is it that makes 
PCPs not address weight loss strategies?   
Weight stigmatization affects obese individuals every day and opportunities for 
improvement in the workplace, schools, healthcare, and media are beginning to be discussed at a 
federal level (Pearl, 2018).  As providers, overcoming weight stigmatization and incorporating 
the SDT as a model of practice could have positive results on weight management.  Helping 
individuals adopt coping strategies to deal with stigmatization and emotional distress will 
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advance weight loss management and facilitate opportunities for intervention and improve social 
identity (Pearl, 2018; Puhl et al., 2017). 
Is it possible that weight stigmatization is what drives individuals to a weight loss clinic? 
They may feel that talking to the PCP and asking for a weight loss medication is a sign of 
weakness or they will be lectured on diet and exercise compliance.  In one study, patients stated 
they let comorbidities exacerbate to a severe degree before seeking care because they wanted to 
avoid feeling shamed by their provider (Okwerekwu, 2016).  All healthcare providers are 
encumbered to recognize obesity as a disease and treat as aggressively as they may treat heart 
disease but approach the issue without bias.   
Limitations 
 Several limitations should be acknowledged.  The generalization of the study was limited 
to data collection only being from one establishment. Due to the rural nature of the clinic, the 
sample size for this project was small and consisted of a significantly non-diverse population. 
Statistical difference between groups could have been limited due to small sample size.  Paper 
documentation of patient health records increased the difficulty and time constraint of data 
collection limiting the number of participants, accuracy of information input, and amount of data 
collected (lab values, concurrent medications, change in comorbidities, cost per individual).  
Because this study was retrospective, verification of reported results was not possible.  
Compliance of diet, exercise, and medication regimen could have skewed results. 
Conclusion 
 Rates of obesity are predicted to rise, with attention to the severely obese subgroup (BMI 
>40) which is increasing rapidly (Gotthardt & Bello, 2016; Sturm & Hattori, 2013; Velazquez & 
Apovian, 2018).  Although not a cure all, anti-obesity pharmacotherapy serves as a part of the 
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solution for the obesity epidemic in the U.S. (Gomez & Standford, 2018).  It is important to note, 
pharmacotherapy is an adjunctive therapy to diet and exercise and has not proven significant 
weight loss without adherence to a diet and exercise plan.  Discussion of weight loss medication 
should be included with every overweight/obese individual that falls in to recommended 
guidelines.  PCPs with time constraints or lack of knowledge about medication should refer 
patients to weight loss clinics but all providers have to be communicating.  
Despite clinically significant weight loss achieved with newer antiobesity drugs such as 
Saxenda, only a small portion of eligible patients are using them due to high cost (Gadde et al., 
2018).  Quality driven healthcare initiatives along with Federal and State coverage mandates 
could make way for change in the coverage of obesity medications (Gomez & Stanford, 2018).  
In policy, providers are the patient advocate; as providers, staying informed and engaged in 
health care policy changes is imperative for change.   
It took 50 years to publicize the link between tobacco use and lung cancer (Malhotra, 
2016).  Big Tobacco companies fought regulation, but through taxation and guidelines in 
advertising, the government substantially declined tobacco consumption over the past three 
decades (Malhotra, 2016).  This was the single most important factor in decreasing 
cardiovascular mortality during this period.  Obesity is the new tobacco and will take a concerted 
effort to reverse the upward trend.   
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